JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online April 20, 2009, 10.2967/jnumed.108.057216
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.057216v1
50/Suppl_1/31S    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hicks, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hicks, R. J.
Journal of Nuclear Medicine Vol. 50 No. Suppl_1 31S-42S
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.057216

Role of 18F-FDG PET in Assessment of Response in Non–Small Cell Lung Cancer

Rodney J. Hicks

Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and University of Melbourne, Parkville, Victoria, Australia

Correspondence: For correspondence or reprints contact: Rodney J. Hicks, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St. Andrew's Pl., East Melbourne, Victoria 3002, Australia. E-mail: rod.hicks{at}petermac.org

Despite recognized limitations, structural imaging with CT remains the standard technique for evaluating the response of lung cancer to both chemotherapy and radiotherapy. This evaluation has become increasingly important with the advent of neoadjuvant therapy before surgery. The high uptake of 18F-FDG in most lung cancers and the demonstration that successful treatment reduces uptake have led to increasing enthusiasm for the use of PET and PET/CT to assess the therapeutic response. In this review, theoretic considerations and current evidence supporting the role of 18F-FDG PET are discussed.

Key Words: molecular imaging • oncology • PET/CT • 18F-FDG • lung cancer • response monitoring

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.




This article has been cited by other articles:


Home page
 JNMHome page
W. A. Weber
Assessing Tumor Response to Therapy
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.